Lilly’s Tirzepatide Effective, But Tolerability Still A Limitation
Drug Reduces A1C, Weight In Diabetes
Tirzepatide’s efficacy seems to outweigh tolerability concerns at the lower doses, but the highest dose may be relegated to niche use.
You may also be interested in...
Lilly outlined its tirzepatide-led pipeline of incretin agonists and highlighted its once-weekly basal insulin during a post-ADA event. The company hopes to grow the GLP-1 market overall rather than shift patients from Trulicity.
The dual GLP-1/GIP agonist outpaced Novo's blockbuster GLP-1 analogue at all three doses, including the important low dose, on A1C reduction and weight reduction in patients with type 2 diabetes.
Starting patients on a low dose yielded lower rates of GI adverse events for the GIP/GLP-1 agonist, but it remains uncertain how differentiated tirzepatide will be against entrenched GLP-1 rivals.